Retatrutide is a triple agonist that targets GLP-1, GIP and glucagon receptors, giving it the broadest receptor profile currently under investigation among incretin peptides
Bhasin S, Brito JP, Cunningham GR, et al
The American Diabetes Association (ADA) and American College of Physicians (ACP) emphasize individualized treatment approaches for glucose-lowering medications, though specific guidance on treatment interruption and resumption is limited
Diabetic retinopathy complications in patients with diabetes, especially with rapid glucose improvement
The standard formulation is designed to deliver precise amounts of the active ingredient, allowing healthcare providers to prescribe it with confidence based on established clinical guidelines
Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, et al